41 results about "Nasal inflammation" patented technology

This invention provides a medicinal ointment for treating rhinitis based on a traditional Chinese medicine compound and its preparation method, relating to the field of traditional Chinese medicine technology. The medicinal ointment for treating rhinitis based on a traditional Chinese medicine compound comprises the following components in parts by weight: Bupleurum chinense 2-10 parts, Dictamnus dasycarpus root bark 3-7 parts, Magnolia biondii flower 8-12 parts, Xanthium sibiricum fruit 4-10 parts, Centipeda minima 2-6 parts, Liquidambar formosana fruit 6-10 parts, Chrysanthemum indicum flower 6-10 parts, Angelica dahurica root 6-12 parts, Houttuynia cordata flower 8-12 parts, Borneol 1-3 parts, Menthol 1-3 parts, Ligusticum chuanxiong rhizome 5-13 parts, Scutellaria baicalensis root 8-12 parts. The ingredients are: 5-11 parts licorice root, 9-10 parts calamus, 1-5 parts Fritillaria thunbergii, 2-6 parts Gleditsia sinensis thorns, 6-10 parts Saposhnikovia divaricata, 8-12 parts Cynanchum paniculatum, 3-9 parts Kochia scoparia, 1-2 parts artificial musk, 5-8 parts ginger, 3-4 parts myrrh, 4-6 parts Schisandra chinensis, 1-3 parts petrolatum, 1-3 parts beeswax, and 2-3 parts coconut oil. In this invention, myrrh reduces acute inflammatory reactions of the nasal mucosa through its anti-inflammatory effect, while Schisandra chinensis reduces secretions through its astringent effect. The combination of the two can effectively relieve nasal congestion and runny nose symptoms.

The application discloses an ear-nose-throat department rhinitis and rhinosinusitis nasal cavity flushing device, and belongs to the technical field of medical instruments, which comprises a flushing liquid injection mechanism and an inner-outer cannula breathing mechanism which are used in cooperation, wherein the flushing liquid injection mechanism comprises a liquid storage bag and a first conducting pipe, the first conducting pipe is connected with the liquid storage bag through a liquid delivery pipe, a nasal cavity liquid supply assembly and a nasal cavity foreign matter cleaning assembly are arranged on the first conducting pipe, and the nasal cavity liquid supply assembly is used in cooperation with the liquid delivery pipe; the inner-outer cannula breathing mechanism comprises a second conducting pipe, and a flushing liquid discharge assembly and a positioning assembly are arranged on the second conducting pipe; through the arrangement of the flushing liquid injection mechanism and the inner-outer cannula breathing mechanism, the device can effectively clean the nasal cavity of a patient, meets the demand of different cleaning modes, and has the characteristics of good cleaning effect, simple and convenient use and low manufacturing cost.

A method for determining the indication for the prevention of persistent AR in the form of problem-based learning in primary school children, consisting of determining the body mass index (BMI, kg / m 2 ) within the range of +1 SDS or more, taking into account the age and sex of the child and IL 1β using the enzyme immunoassay method; with IL 1β equal to or more than 0.029 pg / ml, a child with overweight / obesity is classified as being at high risk for the development of persistent AR, requiring prevention in the form of problem-based learning.

The present invention provides an aqueous solution composition capable of rapidly preventing, alleviating or eliminating symptoms of acute respiratory diseases by applying a hypertonic aqueous solution composition containing molecular iodine to all parts of the eyes, oral cavity, nasal cavity, and respiratory tract. The present invention provides a hypertonic aqueous solution composition containing molecular iodine, which can prevent and eliminate acute respiratory infectious diseases such as cold, flu, and COVID-19, and can rapidly alleviate or eliminate runny nose and nasal congestion caused by allergic and non-allergic rhinitis.

The utility model discloses a red light treatment device for treating allergic rhinitis belongs to medical instrument technical field. It includes laser head and medicine box, and medicine box detachable installation is in the laser emission end of laser head, and medicine box is provided with the through -hole of the laser of laser head, and the cavity for accommodating medicine is arranged to the lateral wall of medicine box, and a plurality of volatile holes are arranged to the lateral wall of medicine box, and the through -hole with cavity are communicated with volatile hole. The end of laser head is installed with medicine box and is inserted into the nostril, and the laser such as red light irradiation of laser head is used for inhibiting the inflammation reaction of nasal mucosa, and along with the slow rise of temperature, the medicine in medicine box will accelerate the volatilization, and under the warm state, the absorption efficiency of nasal cavity to medicine will be increased, that is, through the synergies of red light treatment of laser head and the volatilization and outflow of medicine, can effectively alleviate the symptoms of rhinitis such as allergic rhinitis, reach better treatment effect, and the operation is simple, is applicable to family and medical place.

This invention discloses a compound ointment for protecting the nasal mucosa and repairing skin damage, and its preparation method, belonging to the field of pharmaceutical technology. The compound ointment is formulated with Sophora japonica fruit extract, erythromycin ointment, vitamin B6, levofloxacin hydrochloride tablets, loratadine tablets, fluticasone propionate nasal spray, sesame oil, and honey in specific weight proportions. The components work synergistically, providing protection for the nasal mucosa, treatment of rhinitis, reduction of cold air and external pollutant intrusion, and prevention of colds. It can also treat hemorrhoids, scars, eczema, and other skin damage, achieving "one medicine for multiple uses." This compound ointment has a stable dosage form, is convenient to use, has high utilization rate, high safety, and no obvious side effects, making it suitable for various populations and possessing good industrialization prospects.

A homogeneous polysaccharide from Tussilago farfara, and a preparation method therefor and a use thereof, relating to the technical field of medicine. The homogeneous polysaccharide from Tussilago farfara has a molecular weight ranging from 2.0×103 Da to 4.5×103 Da, and comprises fructose and glucose, wherein the molar ratio of the fructose to the glucose is 20.00-26.00:1.00. The homogeneous polysaccharide from Tussilago farfara has good effects in preventing and treating asthma, rhinitis, cough and chronic obstructive pulmonary diseases.

The present application aims to provide a novel peptide which shows a rapid effect of drug efficacy and potency and has a long relief maintenance period, a medicament and an external agent containing the same, and particularly a preventive or therapeutic agent for dermatitis, rough skin, rhinitis, alopecia, thin hair, a hair growth agent, a hair growth promoting agent, an antipruritic agent, a skin care product, and the like. The present application achieves the above aim by providing an amino acid sequence represented by Formula I, a cyclic peptide or a derivative thereof having no peptide bond other than between the amino acids constituting the amino acid sequence, or a pharmaceutically acceptable salt thereof.

This invention discloses a traditional Chinese medicine composition for treating allergic rhinitis and its application, relating to the field of allergic rhinitis treatment technology. It comprises: 12-18 parts Astragalus membranaceus, 8-12 parts Codonopsis pilosula, 6-10 parts medicated leaven (processed with styrax), 5-9 parts Lilium brownii, 5-10 parts Platycodon grandiflorus, 4-7 parts Prunus mume, 3-5 parts Cicadae periostracum, 2-4 parts Xanthium sibiricum (processed with styrax), and 2-4 parts Glycyrrhiza uralensis (processed with styrax). This invention scientifically combines Astragalus membranaceus and Codonopsis pilosula (for invigorating qi and strengthening the exterior), Xanthium sibiricum (processed with styrax) and Cicadae periostracum (for dispelling wind and opening the orifices), Lilium brownii and Prunus mume (for astringing the lungs and nourishing the blood), medicated leaven (processed with styrax) for strengthening the spleen and harmonizing the middle jiao, and Platycodon grandiflorus and Glycyrrhiza uralensis (processed with styrax) for harmonizing the various herbs. The proportions of each group can produce a synergistic effect, which can not only effectively relieve the external symptoms of allergic rhinitis such as nasal congestion, runny nose, sneezing, and nasal itching, but also improve the patient's allergic constitution and enhance immune tolerance by invigorating qi and strengthening the exterior, regulating lung and spleen functions, thereby reducing the recurrence rate and achieving a therapeutic effect that addresses both the symptoms and the root cause of allergic rhinitis.

The application belongs to the technical field of biological medicine, and particularly relates to a binding molecule targeting CCL5 and application of the binding molecule in combination with drugs in treatment of Th2-type inflammation related diseases. The application discloses use of a binding molecule targeting CCL5 or a pharmaceutical composition comprising the binding molecule in preparation of a product having one or more of the following functions: 1) prevention and / or treatment of Th2-type inflammation related diseases; 2) reduction of skin lesion tissue thickness; 3) reduction of clinical score of atopic dermatitis; 4) reduction of scratching behavior; 5) reduction of tissue damage; 6) alleviation of inflammatory reaction and inhibition of expression of inflammatory factors; and 7) reduction of inflammatory cell infiltration. The binding molecule targeting CCL5 or the pharmaceutical composition comprising the binding molecule has important value in prevention and treatment of immune inflammatory diseases such as atopic dermatitis, allergic rhinitis, asthma, food allergy or drug allergy.

This invention belongs to the field of pharmaceutical technology. Addressing the problem that current TCM treatments for allergic rhinitis-asthma syndrome primarily rely on literature review and the experience of renowned practitioners, lacking clinically validated and fixed-composition TCM formulas, this invention proposes a TCM composition, a TCM preparation, its preparation method, and its application. The TCM composition provided by this invention is made from the following raw materials in parts by weight: Bupleurum chinense 3-10 parts, Angelica sinensis 6-15 parts, Paeonia lactiflora 6-15 parts, Magnolia biondii 6-15 parts, Cicadae periostracum 3-12 parts, Perilla frutescens 6-15 parts, Citrus reticulata 6-15 parts, Fritillaria cirrhosa 2-10 parts, Astragalus membranaceus 10-30 parts, Atractylodes macrocephala 10-30 parts, Saposhnikovia divaricata 6-12 parts, and Glycyrrhiza uralensis 3-12 parts. This invention can effectively improve the disease control level of CARAS patients, increase asthma control test scores, significantly reduce allergic rhinitis control symptom scores, significantly improve quality of life, and significantly alleviate clinical symptoms. Specifically, it promotes the recovery of disease and lung function by regulating immunity, increasing IFN-γ levels, reducing eosinophil infiltration, and improving chronic airway inflammation.

This invention relates to the field of biomedical technology and proposes a biomarker for reflecting the efficacy of hormone therapy for allergic rhinitis and its application. The biomarker includes one or more combinations of IFNGR1, Furin, and CSF1R. The biomarkers IFNGR1, Furin, and CSF1R of this invention can all differentiate between hormone-sensitive and hormone-insensitive rhinitis. Their expression levels in the nasal secretions of patients with hormone-insensitive allergic rhinitis are significantly lower than those of patients with hormone-sensitive allergic rhinitis, thus reflecting the efficacy of hormone therapy for allergic rhinitis. Furthermore, compared with a single biomarker, the combination of the three biomarkers has better discriminative ability and better efficacy, providing important evidence for subsequent treatment of allergic rhinitis.

This application provides a hUC-MSC cell suspension formulation for treating allergic rhinitis and its preparation method. It comprises mammalian stem cells, a pharmaceutically acceptable suspension carrier, and a protective agent. The mammalian stem cells are mesenchymal stem cells, which can be derived from the human umbilical cord. The formulation is suitable for intravenous administration. The preparation method includes: washing the resuscitated stem cells with phosphate buffer, centrifuging, resuspending them in a suspension carrier, adding the suspension carrier and protective agent, and mixing thoroughly. Experiments show that this formulation can reduce the levels of interleukin-4 and interleukin-5 in the serum and spleen of mice with allergic rhinitis, and alleviate inflammatory cell infiltration in the nasal mucosa.

This document discloses an apparatus and method for treating conditions such as rhinitis, wherein a distal end of a probe shaft is introduced through the nasal cavity, the distal end having an end effector having a first configuration with a low profile shaped to manipulate tissue within the nasal cavity. The distal end can be positioned near a nasal tissue region having at least one nasal nerve. Once properly positioned, the distal end can be reconfigured from the first configuration to a second configuration shaped to contact and follow the nasal tissue region, and at least one nasal nerve can subsequently be ablated via the distal end. Ablation can be performed using various mechanisms (e.g., cryotherapy) and optionally under direct visualization.

This invention provides a method for preparing a thermosensitive gel for the prevention and treatment of nasal diseases and its application. By weight and volume percentage, it comprises recombinant human type III collagen, mussel adhesive protein, an anti-allergy agent, traditional Chinese medicine extracts, thermosensitive materials, and a sodium pyruvate-cocamidopropyl betaine ion-pair complex. This invention, by pre-forming the ion-pair complex, simultaneously solves the technical problems of existing nasal gels, such as poor anti-dilution ability, short adhesion time, and easy inactivation of active ingredients. The product is liquid below 30°C and can be sprayed for complete nasal coverage. At body temperature, it transforms into a gel within 2 minutes for long-lasting adhesion, exhibiting rapid anti-inflammatory, nasal patency-clearing, antipruritic, and mucosal repair effects. It is suitable for the prevention and treatment of allergic rhinitis and sinusitis, as well as nasal wound care, with significantly better efficacy than similar commercially available products.

The application discloses an allergic rhinitis nasal cavity flushing device and relates to the technical field of nasal cavity cleaning. The device comprises a handle, a mounting frame is fixedly arranged on the top of the handle, a liquid containing cylinder is threadedly connected to the mounting frame, an electric heating pipe is arranged on the upper portion of the mounting frame and located at the bottom of the liquid containing cylinder, and a pressurizing head is arranged at the bottom of the liquid containing cylinder and extends into the liquid containing cylinder. The liquid containing cylinder is connected to the mounting frame through threads, the outer wall limiting block is inserted into the L-shaped slot in the mounting frame and then is rotated into the limiting slot, and the mounting is fast and stable in cooperation with the positioning cylinder. The waste liquid cylinder, the liquid containing cylinder and the waste liquid cylinder and the partition plate and the waste liquid cylinder are all threadedly connected, the partition plate is provided with a rotating plate, the waste liquid cylinder is provided with an anti-skid block, and the device is convenient to disassemble and clean. The pressure pump in the handle can adjust the flushing pressure, the electric heating pipe can heat the flushing liquid, the temperature sensor, the display screen and the like can be used for accurately controlling the temperature, the liquid receiving plate and the flow guide plate can efficiently collect the waste liquid, pollution is prevented, and the experience is improved.

1. Name of the product in this design: Rhinitis Treatment Device (HD-433). 2. Application of this design: This design is used for the treatment of the nose, component 1 is used for treating the nose, and component 2 is used for physiotherapy of the skin. 3. The key design feature of this product is its shape. 4. The image or photograph that best illustrates the design points: Combination state diagram 7. 5. Other situations requiring explanation: This design is a component product, component 1 is the main body of the therapeutic device, and component 2 is the pulse pen.

This invention discloses a traditional Chinese medicine (TCM) formula, preparation method, and application method for nebulization of rhinitis, belonging to the field of TCM technology. It aims to address the problems of insufficient safety, weak targeting, and poor efficacy of existing TCM nebulization solutions for rhinitis. Based on the principle of syndrome differentiation and treatment, this TCM formula is divided into general basic type, wind-cold type, wind-heat type, lung deficiency type, and damp-heat type specific formulas. It uses Xanthium sibiricum, Magnolia biondii, and Mentha haplocalyx as nasal decongestant ingredients, combined with appropriate auxiliary herbs to precisely match the pathogenesis of different rhinitis syndromes. The invention also discloses the formula preparation and nebulization method, including herb processing, decoction, and nebulization operations, strictly controlling parameters to adapt to the physiological characteristics of the nasal cavity. This invention's formula is safe and non-toxic, with low mucosal irritation, strong adaptability to different syndrome types, simple operation, and sufficient drug release. It can effectively relieve discomfort such as nasal congestion, runny nose, and nasal itching caused by various types of rhinitis, making it suitable for home and primary healthcare institutions. It has good clinical application value and practicality.

The application discloses an allergic rhinitis mask with an externally-arranged replaceable chrysanthemum rhinocleisis sachet interlayer, relates to the technical field of health appliances, and aims to solve the technical problem that current masks lack a structure for placing a rhinocleisis sachet, comprising a mask main body composed of a main body support layer and a skin contact layer, the two sides of the mask main body being connected with ear ropes, the main body support layer being provided with an external structure at a position corresponding to the nose wing part of a user, the external structure comprising a medicine placement interlayer, and the medicine placement interlayer being externally provided with a cloth cover. The external structure is connected with the outer wall of the nose wing part of the main body support layer through the structure, the medicine placement interlayer is connected with the main body support layer as the core of the external structure, a zipper structure is arranged above the medicine placement interlayer, a clamping groove structure is arranged in the slot of the medicine placement interlayer and the main body support layer and is fixed with the medicine placement interlayer, and the sachet is detachably arranged in the groove body of the clamping groove structure, so that the combination effect of mask protection and auxiliary treatment of traditional Chinese medicine in the chrysanthemum rhinocleisis sachet is effectively improved.

Devices and methods for more effective cryoablation of a posterior nasal nerve. The cryoablation tip of the device is paddle-shaped, with broad, flat, overall rectangular outline with notches on the sides to create a metacentric outline. One side of the cryoablation tip is conductive, while the opposing side is highly non-conductive. Corner portions of the tip are also non-conductive. Intermediate portions of the side-edge surfaces conductive, and are configured as recesses or notches in the side edge. In use, the system will be inserted into the nasal cavity of a patient, with conductive surfaces of the cryoablation tip disposed in contact with portions of the turbinate lining overlying a posterior nasal nerve, and operated to cool those portions to ablate the posterior nasal nerve. The insulative portion of the cryoablation tip protects remaining surrounding tissue from cryoablation.

This invention relates to the application of Lactobacillus acidophilus CL-01 in the preparation of products for relieving pollen-induced allergic rhinitis; the CL-01 strain is Lactobacillus acidophilus with accession number GDMCC No:64731. Lactobacillus acidophilus CL-01 strain. This invention develops a new use for Lactobacillus acidophilus CL-01, providing a research basis for its widespread application. It also develops a novel strategy for alleviating pollen-induced allergic rhinitis. This invention finds that Lactobacillus acidophilus CL-01 has a very significant effect in alleviating symptoms related to pollen-induced allergic rhinitis, specifically by significantly improving symptoms such as nasal mucosal lesions, nasal itching, sneezing, runny nose, asthma, and intestinal flora imbalance caused by pollen-induced allergic rhinitis.

This invention provides a traditional Chinese medicine composition for treating allergic rhinitis, its preparation method, and its application. The effective components of the traditional Chinese medicine composition are made from the following raw materials in parts by weight: Astragalus membranaceus 3-50, Atractylodes macrocephala 3-30, Saposhnikovia divaricata 3-30, Magnolia biondii 3-30, Xanthium sibiricum (fried) 3-30, Ganoderma lucidum 3-50, Platycodon grandiflorus 3-30, calcined dragon bone 5-50, calcined oyster shell 5-50, Terminalia chebula 3-30, Adenophora stricta 3-30, Cordyceps sinensis mycelium powder 3-30, and Dictamnus dasycarpus 3-30. The raw materials of this traditional Chinese medicine composition are common, the preparation method is simple and easy to operate, and it has wide application value. Oral administration of the drug significantly improves nasal sensitivity symptoms in a mouse model of allergic rhinitis, reduces the levels of IgE and histamine in serum and nasal lavage fluid, reduces the level of inflammatory factors in serum, and inhibits the number of inflammatory cells and mast cells in the nasal mucosa, thus effectively treating allergic rhinitis.

The application relates to a preparation method and application of a novel composite hydrogel for improving nasal symptoms, and belongs to the technical field of hydrogel preparation. In order to solve the problems of easy inactivation, easy removal and strong stimulation of a volatile oil nasal delivery system in the prior art, the application provides a novel composite hydrogel for improving nasal symptoms. Through the synergistic effect of group functionalization mesoporous inorganic carriers, nanoemulsions and temperature-sensitive hydrogels, a double-response nasal drug delivery system is constructed, various natural medicinal volatile components can be widely loaded, drug stable protection, controlled release and target retention are realized, and a safe, efficient, good compliance, widely popularized innovative drug delivery strategy is provided for improving nasal symptoms, allergic rhinitis and other nasal diseases.

The application discloses a traditional Chinese medicine composition for treating rhinitis and belongs to the technical field of traditional Chinese medicine compositions, which is prepared from magnolia, xanthium sibiricum, eupatorium fortunei, ligusticum sinense, chuanxiong rhizome, houttuynia cordata, baizhi, platycodon grandiflorum, dried tangerine or orange peel, wild chrysanthemum and agastache rugosa. In the application, magnolia and xanthium sibiricum are monarch drugs, and are matched with eupatorium fortunei to directly pass through the orifices of the body and rapidly relieve nasal congestion; houttuynia cordata and wild chrysanthemum clear heat and resolve toxins, reduce the performance of inflammatory factors in the nasal cavity, chuanxiong rhizome, baizhi and ligusticum sinense promote blood circulation and dispel wind, go up to the head and improve local microcirculation and headache; platycodon grandiflorum carries drugs to go up, dried tangerine or orange peel and agastache rugosa eliminate dampness and harmonize the center, can be acrid and dispersing, warm and unblock, rapidly relieve the congestion and edema of the nasal mucosa, restore the ventilation function of the nasal cavity, achieve the effects of unblocking the orifices of the body, resisting inflammation and strengthening the body resistance.

This invention provides a topical Chinese medicine ointment that is fast-acting and effective in preventing and treating allergic rhinitis. The drug composition in this invention can quickly clear nasal passages, clear heat and detoxify, reduce inflammation and swelling, and stop nasal discharge, thereby relieving symptoms and reducing the possibility of recurrence. The topical application of this Chinese medicine ointment is easier to adhere to, and it does not have the side effects of Western medicine hormones. It can fundamentally protect the nasal mucosa, reduce the invasion of allergens, improve symptoms, and reduce the recurrence rate.

A lung-clearing and nasal-relieving essential oil for relieving rhinitis symptoms and its preparation method, comprising the following raw materials in parts by weight: 40-70 parts sweet almond oil, 10-30 parts refined jojoba oil, 2-10 parts Cuban balsam essential oil, 1-5 parts neroli essential oil, 1-5 parts sweet laurel essential oil, 1-5 parts black peppermint essential oil, 1-5 parts Australian eucalyptus essential oil, 1-5 parts fir essential oil, 1-3 parts bitter orange essential oil, 1-4 parts magnolia essential oil, and 1-4 parts perilla essential oil. This essential oil can effectively relieve rhinitis-related problems such as nasal congestion, runny nose, sneezing, nasal itching, decreased sense of smell, dizziness, and headache. All essential oils use natural plant extracts, greatly reducing the risk of adverse reactions and making it suitable for long-term use.

This invention belongs to the field of traditional Chinese medicine technology, specifically relating to a traditional Chinese medicine composition for the prevention and treatment of allergic rhinitis, its preparation method, and its application. The raw materials of the traditional Chinese medicine composition of this invention, by weight, consist of the following components: Astragalus membranaceus 20-60 parts, Angelica sinensis 10-30 parts, Saposhnikovia divaricata 10-30 parts, Atractylodes lancea 9-30 parts, Acorus tatarinowii 9-40 parts, Asarum heterotropoides 3-15 parts, Ligusticum chuanxiong 8-30 parts, and Angelica dahurica 6-20 parts. The traditional Chinese medicine composition for the prevention and treatment of allergic rhinitis provided by this invention can strengthen the lungs and wei qi, clear nasal passages, and relieve pain and itching, exhibiting significant preventive and therapeutic effects on allergic rhinitis.

This invention belongs to the field of biomedical technology, specifically relating to an umbilical cord MSC exosome nanocarrier delivery system and its application in the preparation of drugs for treating allergic rhinitis. This invention prepares the umbilical cord MSC exosome nanocarrier delivery system by adding a specific concentration of diosgenin to the culture medium of umbilical cord mesenchymal stromal cells (MSCs), collecting the cell culture supernatant, and separating and extracting it. Animal experiments show that the delivery system prepared in this invention significantly improves the symptoms of nose scratching and sneezing in mice with allergic rhinitis. Its mechanism of action lies in effectively regulating the Th1 / Th2 immune balance: significantly inhibiting the overexpression of the pro-inflammatory factor IL-4, while simultaneously restoring the anti-inflammatory factor IL-10, thus avoiding immune dysregulation. This invention provides a safe and effective new treatment for allergic rhinitis and has good clinical application prospects.

The application discloses an electronic atomizer with a nasal function, comprising a shell, an atomizing chamber, a battery, a bottom cover and a microphone, wherein the atomizing chamber and the battery are arranged in the shell in an up-down distribution mode, the bottom cover is arranged on the bottom of the shell, the top of the shell is provided with a nasal suction part, the upper side of the shell is provided with a decoration part, and the decoration part comprises a fixing part, a hanging rope part and a cap, wherein the fixing part is fixedly arranged on the outer side of the shell, and the hanging rope part and the cap are respectively connected to the outer side of the fixing part. The electronic atomizer with the nasal function meets different smoking requirements of electronic cigarette smokers through the design of the nasal suction part, prolongs the time of smoke in the nasal cavity to be heated and fully oxidized, and meanwhile, the temperature of the smoke entering the body is moderate through the adjusting effect of the nasal cavity, so that the influence of the overhot or overcold smoke on the respiratory system is avoided, in addition, receptors on the nasal mucosa can transmit the information of the smoke to the brain, so that a stronger stimulation feeling is generated. For patients with rhinitis, the nasal treatment effect can be greatly improved.

1. Name of the product in this design: Fog reservoir (for both mouth and nose). 2. Intended use of this design: an inhalation device for the simultaneous treatment of rhinitis, asthma, adenoid hypertrophy, allergic rhinitis-asthma syndrome, chronic cough, and COPD. 3. The key design feature of this product is its shape. 4. The picture or photo that best illustrates the key design points: Design 1 Combined State Diagram 1. 5. Design 1 is designated as the basic design. 6. Other situations requiring explanation: In the 3D diagram of component 1, part A is made of transparent material.